How a Pharmaceutical company banked in millions on Melanotan and what it means for you
“Vyleesi is the first and only FDA-approved as-needed treatment for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).”
Vyleesi is the brand name for Bremelanotide, which is a non-selective agonist of the melanocortin receptors, MC1 through MC5 (with the exception of MC2, the receptor of ACTH), but acting primarily as an MC3 and MC4 receptor agonist. For those of you biochemistry nerds, this pharmacology may sound familiar, similar, or even the same as Melanotan 2? That’s because it is—almost—pretty much identical to Melanotan 2. Pharmaceutical companies often make seemingly minor and insignificant changes to parent compounds so they can claim a medication as their own invention. There is more politics to it all, but in the case of Melanotan 2 vs Bremelanotide, the only difference is that Bremelanotide has a hydroxyl group where melanotan-II has an amide. Clinically speaking (meaning real life effects), it seems there is very little, if any difference between the two in practice.
Sneaky pharmaceutical companies hey? Not really. This is big business. There are loop holes in all fields of business. The big boys who have brought Vyleesi to FDA approval have officially provided insight to the safety profile of Melanotan 2 in humans for the first time ever. For that, I thank them. We have enough data now to say that Melanotan 2, if used responsibly, is a relative safe medication with a wide array of potential benefits. These benefits include:
– Increased ability to tan
– Increased insulin sensitivity
– Increased fat loss
– Decreased appetite
– Increased sexual desire
– Increased erectile quality
But what about side effects? At this stage, it seems a modest, maximal increase of 6 mmHg in systolic blood pressure (SBP) and 3 mmHg in diastolic blood pressure (DBP) that peaked between 2 to 4 hours post dose. There was a corresponding reduction in heart rate up to 5 beats per minute. Blood pressure and heart rate returned to baseline usually within 12 hours post-dose. No additive effects were seen for blood pressure or heart rate following repeat daily dosing 24-hours apart for up to 16 days. Nausea and yawning/stretching reflex were the only other common side effects that seem to be dose dependent. The dose of Bremelanotide used to induce sexual desire for women was 1750 mcg, which is a whopper dose if you ask me. Lower doses of Melanotan 2 in my experience can be just as effective, with far lesser side effect potential. I have discussed dosing in this article here.
At this stage guys, it seems that Melanotan 2 is here to stay and is “Dave approved.” Be responsible as always, but get jacked and stay tan.
Useful resources:
https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hypoactive-sexual-desire-disorder-premenopausal-women
https://link.springer.com/article/10.1007/s40263-015-0288-1
I hope this helps! Any specific questions related to this post do not hesitate to ask in the comments section below or email us at info@austeroids.is
– Dave from Austeroids.is